Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

November 12th 2019

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

NGS Testing Is Essential Before Induction in NSCLC

November 12th 2019

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Dr. Borghaei on the Search for Biomarkers in Lung Cancer

November 12th 2019

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Dr. Halmos on Actionable Biomarkers in NSCLC

November 12th 2019

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Dr. Hirsch on the Expansion of Molecular Testing in Lung Cancer

November 12th 2019

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Plasma NGS Demonstrating Practice-Changing Potential in NSCLC

November 12th 2019

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Osimertinib Positioned as Preferred Frontline Treatment for EGFR-Mutant NSCLC

November 12th 2019

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.

Frontline Immunotherapy Firmly Established for Select Patients With NSCLC

November 11th 2019

The use of immunotherapy, either as monotherapy or in combination with chemotherapy, continues to raise the bar with regard to overall survival benefit in patients with newly diagnosed, advanced nonsquamous non–small cell lung cancer.

Dr. Ramalingam on FLAURA Trial Results in EGFR-Mutant NSCLC

November 10th 2019

Suresh S. Ramalingam, MD, FASCO, discusses updated data from the FLAURA trial in EGFR-mutant non–small cell lung cancer.

Role of Neoadjuvant Immunotherapy Being Refined in Resectable NSCLC

November 10th 2019

Neoadjuvant immunotherapy can offer promise to patients with resectable non–small cell lung cancer, but further investigation is required for optimal use, Tina Cascone, MD, PhD, said in a presentation during the 14th Annual New York Lung Cancers Symposium®.

Neoadjuvant Approaches Showcase Advantages in NSCLC

November 10th 2019

Based on efficacy, tolerability, and practicality, neoadjuvant therapy in lung cancer offers significant advantages over adjuvant treatment, said Jamie E. Chaft, MD, in a presentation during the 14th Annual New York Lung Cancers Symposium®. However, she added, adjuvant treatment predominantly remains the standard of care at many cancer centers, she said.

Levy Lends Insight on Evolving Treatment Strategies in Lung Cancer

November 9th 2019

Benjamin P. Levy, MD, discusses therapeutic strategies for patients with oncogenic-driven and nondriver non–small cell lung cancer.

Dr. Lai on the Results of the CASPIAN Trial in Small Cell Lung Cancer

November 9th 2019

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

Research Abounds in Targeting Rare Mutations in Lung Cancer

November 8th 2019

Michael D. Offin, MD, discusses ongoing research focusing on some of the less-common targetable mutations in non–small cell lung cancer.

Spotlighting New Standards in Lung Cancer in Salt Lake City

November 7th 2019

We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.

Dr. Hassan on FLAURA Trial Results in EGFR-Mutant NSCLC

November 6th 2019

Khaled A. Hassan, MD, MS, discusses the results of the FLAURA trial, which compared osimertinib with first-generation TKIs in patients with EGFR-mutant metastatic non–small cell lung cancer.

Chemoimmunotherapy Changes Standard Care in Stage IV Nonsquamous NSCLC

November 6th 2019

Hossein Borghaei, DO, MS, highlights pivotal trials examining chemoimmunotherapy in metastatic nonsquamous non–small cell lung cancer, ongoing research efforts, and exciting biomarkers on the horizon.

Immunotherapy Efforts Forge Ahead in Stage III NSCLC

November 5th 2019

Gregory M. M. Videtic, MD, CM, FRCPC, discusses ongoing developments with immunotherapy in stage III non–small cell lung cancer.

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

November 4th 2019

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.